1437774-71-4

Basic information

• Product Name: tert-butyl 5-[4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-5-phenyl-thieno[2,3-d]pyrimidin-2-yl]oxy-2-azabicyclo[2.2.1]heptane-2-carboxylate
• Synonyms: tert-butyl 5-[4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-5-phenyl-thieno[2,3-d]pyrimidin-2-yl]oxy-2-azabicyclo[2.2.1]heptane-2-carboxylate
• CAS NO: 1437774-71-4
• Molecular Weight: 534.679
• Mol File: 1437774-71-4.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl 5-[4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-5-phenyl-thieno[2,3-d]pyrimidin-2-yl]oxy-2-azabicyclo[2.2.1]heptane-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 5-[4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-5-phenyl-thieno[2,3-d]pyrimidin-2-yl]oxy-2-azabicyclo[2.2.1]heptane-2-carboxylate(1437774-71-4)
• EPA Substance Registry System: tert-butyl 5-[4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-5-phenyl-thieno[2,3-d]pyrimidin-2-yl]oxy-2-azabicyclo[2.2.1]heptane-2-carboxylate(1437774-71-4)

Safety Data

• Hazardous Substances Data: 1437774-71-4(Hazardous Substances Data)

Upstream product

• 904316-92-3 3-oxa-8-azabicyclo[3.2.1]octane hydrochloride 
• 207405-60-5 (1R,4R)-1,1-Dimethylethyl 5-hydroxy-2-azabicyclo[2.2.1]heptane-2-carboxylate 
• 1437774-70-3 8-(2-chloro-5-phenyl-thieno[2,3-d]pyrimidin-4-yl)-3-oxa-8-azabicyclo[3.2.1]octane 
• 76872-27-0 2,4-dichloro-5-phenyl-thieno[2,3-d]pyrimidine 

Downstream Products

• 1437773-88-0 8-[2-(2-azabicyclo[2.2.1]heptan-5-yloxy)-5-phenyl-thieno[2,3-d]pyrimidin-4-yl]-3-oxa-8-azabicyclo[3.2.1]octane 

Relevant articles and documents

THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS

The present invention provides compounds of formula (I): (Formula (I); wherein A, R1, R2, R3I, V, X, and Z are defined herein, which are potassium channel inhibitors. The invention further provides pharmaceutical compositions comprising the compounds of formula (I) and their use in therapy, in particular in treatment of diseases or conditions that are mediated by Kir3.1 and/or Kir3.4 or any heteromultimers thereof, or that require inhibition of Kir3.1 and/or Kir3.4 or any heteromultimers thereof.